ANN ARBOR, MI – NOVEMBER 19: Jabrill Peppers #5 of the Michigan Wolverines leaves the field after a 20-10 win over the Indiana Hoosiers on November 19, 2016 at Michigan Stadium in Ann Arbor, Michigan. (Photo by Gregory Shamus/Getty Images)Jabrill Peppers arrived at Michigan last year as one of the most heralded recruits in the country. However, his freshman season was cut short due to injury, and he ended up taking a medical redshirt.Michigan began spring drills this week, and judging by this video Peppers posted on Twitter, he’s 100 percent healthy and very fired up to be on the field.TURNT‼️ pic.twitter.com/GrnGLVUX6N— Breez (@JabrillPeppers) February 25, 2015That backflip was in the middle of special teams drills. Imagine how excited Peppers will be when he gets to play in the secondary.It will be interesting to see how Peppers looks in 2015, assuming he stays healthy. He has the ability to be a breakout player for the Wolverines.
Source:https://www.escardio.org/ Reviewed by James Ives, M.Psych. (Editor)Feb 5 2019Anti-inflammatory biologic drugs used to treat severe psoriasis have the potential to prevent heart disease in patients with the skin condition, according to research published today in Cardiovascular Research, a journal of the European Society of Cardiology (ESC). During one year of treatment, biologic therapy improved coronary artery plaque similar to the effect of a low-dose statin.”Psoriasis severity is related to the burden of coronary disease – our findings suggest treating the psoriasis may potentially benefit coronary heart disease,” said study author Dr Nehal Mehta, Chief of Inflammation and Cardiometabolic Diseases at the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, Maryland, US.Psoriasis causes scaly skin patches, often on the elbows, knees, scalp, and lower back. Patients with the skin condition have an elevated risk of heart disease – young patients with severe psoriasis are at twice the risk of having a first heart attack at 40-50 years of age.Psoriasis patients often have inflammation throughout the body and may be treated with anti-inflammatory biologic therapy when their skin condition is severe and topical treatments or phototherapy have failed. This study investigated whether treating severe psoriasis with a biologic could improve the health of the coronary arteries.The study found that patients with severe psoriasis who took biologic therapy for one year had an 8% reduction in total and non-calcified coronary plaque burden, a frequent cause of heart attacks (see figure) – similar to the effect of a low dose statin. The make-up of coronary plaques also improved in those taking biologics, making them less risky. Coronary plaque burden increased by 2% in patients who did not take a biologic.Dr Mehta said: “We found that these anti-inflammatory drugs commonly used to treat severe psoriasis also improve plaque in the coronary artery making them more stable and less likely to cause a heart attack. This occurred in the absence of changes in traditional cardiovascular risk factors including blood pressure and blood lipids.”Related StoriesStroke should be treated 15 minutes earlier to save lives, study suggestsCutting around 300 calories a day protects the heart even in svelte adultsCancer incidence among children and young adults with congenital heart diseaseDuring the one-year study, systemic inflammation assessed by blood markers reduced only in the group taking biologic therapy. Dr Mehta said it is too early to say whether biologics exert their effects on coronary plaques directly or by reducing systemic inflammation.He said: “This preliminary study provides the first evidence that biologic therapy is associated with coronary plaque reduction and stabilization, and provides strong rationale for conduct of a randomized trial testing the impact of biologic therapy on the progression of coronary disease in patients with psoriasis.”Dr Mehta noted that some patients with severe psoriasis opt not to take a biologic medicine because they suppress the immune system and may increase the chance of infection. In addition, they must be injected.Previous research has shown that in heart attack patients, anti-inflammatory biologic therapy reduces the risk of another cardiovascular event.2 “With the results of that study and our current one, my message to patients with psoriasis is to take untreated inflammation seriously,” said Dr Mehta. “When someone has severe psoriasis, they are at higher risk of heart attack and treating the psoriasis may reduce that risk.”The observational study included 121 patients with severe psoriasis who qualified for biologic treatment. Of those, 89 took biological therapy (one of three types) and 32 used topical treatment. All patients underwent imaging of their coronary arteries with computed tomography angiography at baseline and one year later to assess the amount and characteristics of plaques such as the necrotic core which causes plaque rupture.
Reviewed by James Ives, M.Psych. (Editor)Jul 9 2019Scientists at The University of Toledo investigating improvements to a commonly used chemotherapy drug have discovered an entirely new class of cancer-killing agents that show promise in eradicating cancer stem cells.Their findings could prove to be a breakthrough in not only treating tumors, but ensuring cancer doesn’t return years later — giving peace of mind to patients that their illness is truly gone. Taylor and Dr. L.M. Viranga Tillekeratne, a professor in the Department of Medicinal and Biological Chemistry in the UToledo College of Pharmacy and Pharmaceutical Sciences, reported their findings in a paper recently published in the journal Scientific Reports.Cancer stem cells are an intriguing target for researchers because of their potential to re-seed tumors.When doctors remove a tumor surgically or target it with chemotherapy drugs or radiation therapy, the cancer may appear to be gone. However, evidence suggests that a tiny subpopulation of adaptable cancer cells can remain and circulate through the body to seed new metastasis in far-off locations.Those cancer stem cells, Taylor said, are similar to dandelions in a well-manicured lawn.”You could chop the plant off, but it will drop a seed. You know the seeds are there, but they’re hiding,” he said. “You pull one weed out and another comes up right after it. Cancers can be like this as well.”Related StoriesCancer killing capability of lesser-known immune cells identifiedHow cell-free DNA can be targeted to prevent spread of tumorsTrends in colonoscopy rates not aligned with increase in early onset colorectal cancerThe small molecule they have isolated appears to lock on to those stem cells and kill them by blocking their absorption of an amino acid called cystine.UToledo was awarded a patent for the discovery late last year.For Tillekeratne and Taylor, uncovering a new class of therapeutic molecules could prove to be an even larger contribution to cancer research than the project they initially envisioned.”At present, there are no drugs that can kill cancer stem cells, but people are looking for them,” Tillekeratne said. “A lot of drugs are discovered by serendipity. Sometimes in research if you get unexpected results, you welcome that because it opens up a new line of research. This also shows the beauty of collaboration. I wouldn’t have been able to do this on my own, and [Taylor] wouldn’t have been able to do it on his own.”Tillekeratne has received a three-year, $449,000 grant from the National Institutes of Health National Cancer Institute to continue testing the effectiveness of the newly identified therapy.Because the molecules so selectively target cancer stem cells, it’s possible they could ultimately be paired with other chemotherapy drugs to deliver a more comprehensive treatment.However, the researchers have found their agents show stand-alone promise in treating sarcomas and a subtype of breast cancer known as claudin-low breast cancer, which represents up to 14 percent of all breast cancers and can be particularly difficult to treat. Source:University of ToledoJournal reference:Taylor, W.R. et al. (2019) Small-Molecule Ferroptotic Agents with Potential to Selectively Target Cancer Stem Cells. Scientific Reports. doi.org/10.1038/s41598-019-42251-5. Not all cancer cells are the same, even in the same tumor. There is a lot of variability and some of the cells, like cancer stem cells, are much nastier. Everyone is trying to figure out how to kill them, and this may be one way to do it.”Dr. William Taylor, professor in the Department of Biological Sciences, UToledo College of Natural Sciences and Mathematics
© 2018 AFP Summer is the ideal time for breaking out a bottle of rose, but fans of French wine might think twice after millions of bottles were found to contain less costly Spanish tipple instead. Explore further ‘Question of price’Tensions have long simmered between winegrowers on either side of the Pyrenees, with French producers often accusing their Spanish rivals of unfair competition.In recent years French protests have blocked Spanish trucks from bringing their wine into the country, with demonstrators emptying their loads onto highways.Production surpluses in Spain have pushed down prices there, making the country’s wines a better deal for consumers—and a tempting substitute for some French distributors.”It’s a question of price,” Jerome Despey, a winegrower in the southern Herault region and member of the FNSEA agricultural union, told AFP.The two countries’ agriculture ministers met in Paris last summer to try to end the conflict, leading to a series of measures aimed at limiting price volatility, Despey said.Price increases across Europe following weather-related grape harvest shortfalls last year have also helped ease tensions.”We need to keep up the pressure with these inspections so this kind of thing can’t happen again,” Despey said, urging the government to impose stricter labelling rules.Delphine Geny-Stephann, France’s junior economy minister, said she had asked the fraud agency “to continue carrying out regular inspections in the sector.” French winemakers emptying wine from a Spanish truck during a protest Le Boulon, ten kilometres forms the French-Spanish border, in April 2016 French farmers block refineries over palm oil imports This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. Citation: France sees red after Spanish rose wine found in domestic bottles (2018, July 9) retrieved 18 July 2019 from https://phys.org/news/2018-07-france-red-spanish-rose-wine.html French investigators found that millions of bottles of rose actually contained Spanish wine France’s consumer fraud agency confirmed Monday that 70,000 hectolitres—the equivalent of 10 million bottles—of Spanish rose were falsely labelled as French vintages by hundreds of producers in 2016 and 2017.According to French daily Le Parisien, which first reported the findings, Spanish rose sold in bulk at the time for just 34 euro cents ($0.40) a litre compared with 75 to 90 cents for French rose.”We were alerted to the ‘Frenchification’ of Spanish wine at the end of 2015,” the consumer agency’s Alexandre Chevallier told the paper.”So we launched an inquiry at all levels, from producers to importers to restaurants and distributors,” he said.Twenty-two percent of the businesses subjected to controls in 2016 and 15 percent in 2017—a total of 743 establishments—were cited for trying to present the foreign wine as French, he explained. Some blatantly passed it off as French, as was the case for bottles showing drawings of French-sounding but fictitious castles, or wines sold by the glass in some restaurants.Others were more subtle, putting “Produced in France” on the front label but “European Community wine” on the back, or embellishing bottles with national symbols like the heraldic lily or a ribbon in the blue, white and red of the French flag.Misleading wine drinkers is no small matter in France: producers could face fraud lawsuits that carry penalties of up to two years in prison and 300,000 euros in fines.
British electric appliance pioneer Dyson will switch headquarters to Singapore this year due to booming Asian demand but not because of Brexit, the company said Tuesday. © 2019 AFP The group, founded and owned by serial entrepreneur and vocal Brexit supporter James Dyson, last year announced it would produce electric cars in Singapore.The firm stressed that Brexit was not a factor behind the decision to ditch its corporate base in Malmesbury in Wiltshire, western England, in favour of Singapore.Dyson, famed for its cordless vacuum cleaners, hand dryers and fans, now has its sights set on electric vehicles—particularly in Asia.”An increasing majority of Dyson’s customers and all of our manufacturing operations are now in Asia; this shift has been occurring for some time and will quicken as Dyson brings its electrical vehicle to market,” it said in an earnings statement.”As a result, an increasing proportion of Dyson’s executive team is going to be based in Singapore; positioning them to make the right decisions for Dyson in a quick and efficient way.”This does not change any of our investment and recruitment plans; however we are now at a point where Dyson’s corporate head office will relocate there to reflect the increasing importance of Asia to Dyson’s business.”A prototype Dyson electric vehicle is in the works for 2020, followed by a product launch in 2021.’Not related to Brexit’The Singapore move “is not related to Brexit”, chief executive Jim Rowan told reporters on a conference call, noting there was only a “negligible” tax benefit.”We don’t see any issues regarding Brexit,” he said, adding that Dyson’s manufacturing capacity, as well as the majority of its supply base, is in south east Asia.”We are a global technology company,” Rowan insisted, adding that it would continue to invest in home market Britain.Dyson had already announced last October that it had picked Singapore for its first electric car plant, sparking criticism from some quarters that its Brexit-backing billionaire founder had not invested more in the UK.But the group also said in March that it would open a second research and development centre in a former Royal Air Force airfield in Hullavington, southwest England.Meanwhile on Tuesday, Dyson said that 2018 underlying profit—as measured by earnings before interest, taxes, depreciation and amortisation (EBITDA)—surged one third to £1.1 billion (1.2 billion euros, $1.4 billion).Turnover, or sales, rose by 28 percent to stand at £4.4 billion on growing global appetite for cutting-edge technology.”Globally, enthusiastic owners are demanding high-performance products so we are deepening out operations and technology investments to meet their needs,” added Rowan.James Dyson, who owns 100 percent of the company he founded in the 1970s, has revolutionised household appliances with his bagless vacuum cleaners, bladeless fans and air purifiers. Explore further This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. Citation: Dyson switches HQ from Britain to Singapore: company (2019, January 22) retrieved 17 July 2019 from https://phys.org/news/2019-01-dyson-hq-britain-singapore-company.html Leaving Britain, but not because of Brexit Dyson shifts up a gear with electric car hub